Alcon (ALC.SW) Aandeel Koers
Alcon Koers
De omzet is de afgelopen 10 jaar met 4,9% per jaar gegroeid tot 8,86 Miljard USD. De winst per aandeel is de afgelopen 10 jaar met 12,7% per jaar gegroeid. De nettowinstmarge van Alcon ligt op 9,4% en is ten opzichte van 4,5% enkele jaren eerder gestegen. Alcon biedt momenteel een dividendrendement van circa 0,40%. De uitkeringsratio ligt rond 20% van de winst. Het dividend is de afgelopen 4 jaar met 29,4% per jaar gegroeid. Analisten hanteren een mediaan koersdoel van 101,29 USD — dat impliceert 44,0% boven de huidige koers. Van de 20 analisten geven 15 het aandeel een koopadvies — per saldo een Kopen-consensus.
Alcon aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Alcon bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Alcon
The business model of Alcon AG centers around providing innovative eye care solutions and products. As a globally recognized company, Alcon AG specializes in developing, manufacturing, and distributing a wide range of ophthalmic surgical equipment, pharmaceuticals, and consumer eye care products. Their offerings include contact lenses, surgical equipment for cataract and refractive surgeries, as well as prescription and over-the-counter eye care products. With a strong focus on research and development, Alcon AG aims to continuously improve eye health outcomes and enhance vision quality for individuals around the world.
Alcon AG is primarily active in the healthcare and pharmaceutical industries.
The main competitors of Alcon AG in the market are Johnson & Johnson Vision, Bausch Health Companies Inc., and Novartis AG.
Alcon AG is a renowned company with a rich history and background. Established in XYZ, Alcon AG has become a leading player in the industry. The company specializes in XYZ products and services, catering to a wide range of customers worldwide. Over the years, Alcon AG has achieved significant milestones and global recognition for its innovative solutions and exceptional quality. With a strong commitment to excellence, Alcon AG continues to expand its presence and investment in research and development. With a solid track record, Alcon AG has remained a trusted choice for investors seeking growth and reliability in the market.
Alcon AG, a renowned stock, has achieved significant milestones throughout its journey. The company has successfully introduced groundbreaking products and technologies in the field of eye care. Alcon AG's major achievements include the development of revolutionary intraocular lenses (IOLs) that have enhanced vision correction and improved patients' quality of life. Additionally, the company pioneered innovative surgical equipment and techniques, such as advanced phacoemulsification devices, revolutionizing cataract surgery. Alcon AG has dedicated itself to providing cutting-edge ophthalmic solutions, elevating the standards of eye care globally. With its impressive track record, Alcon AG stands out as a leading entity within the stock market.
Alcon AG primarily operates in various countries and regions worldwide. With its global presence, the company has established a strong foothold in key markets across the Americas, Europe, Asia, and Africa. Alcon AG's extensive reach includes countries such as the United States, Germany, Switzerland, France, China, Japan, Australia, South Africa, and many others. The company's strategic expansion allows it to cater to a diverse clientele, providing innovative eye care products and services internationally.
Alcon AG represents a strong commitment to values and a clear corporate philosophy. The company prioritizes integrity, innovation, and excellence in all aspects of its operations. Alcon is dedicated to improving vision care and providing high-quality eye care products and services to its customers. With a focus on continuous research and development, Alcon aims to deliver cutting-edge solutions for eye health. By upholding these values and embracing a forward-thinking approach, Alcon AG sets itself apart as a trusted and leading player in the field of ophthalmic innovation.
Analisten hanteren momenteel een gemiddeld koersdoel van 101,79 USD voor het aandeel Alcon (mediaan: 101,29 USD), oftewel +44,7 % ten opzichte van de laatste koers. De consensus is gebaseerd op 20 analistenratings.
20 analisten beoordelen het aandeel Alcon momenteel: 16 adviseren kopen, 2 houden en 2 verkopen. Voor 2026 verwachten analisten dat Alcon een omzet van 10,91 Miljard USD en winst per aandeel van 3,47 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel Alcon op 63,12 EUR (70,33 USD).
Het aandeel Alcon (ALC.SW) is genoteerd aan 7 beurzen, waaronder: NYSE (ALC), London (0A0D.L), SIX (Zürich) (ALC.SW), Frankfurt (2U3.F), München (2U3.MU), Düsseldorf (2U3.DU), Hamburg (2U3.HM).
Alcon AG is a global company that offers a wide range of eye care products for patients and medical professionals. The company specializes in developing and manufacturing innovative solutions for optimal vision and eye health. Alcon operates in over 75 countries worldwide. Alcon has five main business areas: Surgery, Vision Care, Pharma, Ophthalmic Devices, and Ophthalmic Instruments. The Surgery division specializes in surgical procedures such as cataract surgery and retinal surgery. The Vision Care division deals with contact lenses, glasses, and other vision correction products. The Pharma division includes medications for treating eye diseases such as glaucoma and allergic conjunctivitis. The Ophthalmic Devices and Ophthalmic Instruments divisions specialize in medical accessories and instruments. Alcon's most well-known product is the Air Optix contact lens, available in various designs and materials, which allows for longer wear time. The Dailies contact lens line and the TrueTear therapy for dry eyes are also popular Alcon products. Alcon has also developed some innovative technologies, including the ORA System, which allows for more precise measurements of eye data during cataract surgery, and the WaveLight Refractive Suite for correcting refractive errors such as myopia, hyperopia, and astigmatism. Another important product from Alcon is Restasis, a medication for treating dry eyes. It is the first FDA-approved medication to stimulate natural tear production. Alcon's business model is based on innovation and quality. The company heavily invests in research and development to develop the eye care solutions of the future. Alcon also has a strong presence in the education and training of eye doctors and other medical professionals. The company offers training and continuing education to keep doctors and professionals up to date and help them utilize Alcon's innovative technologies and products. Alcon also has a strong online presence and offers a wide range of digital resources, including online training, resources for medical professionals and patients, and videos on eye care products and technologies. Overall, Alcon is a leading company in the eye care industry that focuses on innovation and quality. With a wide range of products and services and a strong presence in medical education and training, Alcon is well positioned to continue growing and improving eye health and vision worldwide.
De verwachte omzet van Alcon bedraagt 10,91 Miljard USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van Alcon bedraagt 1,71 Miljard USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Alcon bedraagt momenteel 20,27. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Alcon-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Alcon bedraagt momenteel 3,17. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Alcon-aandeel.
De Eulerpool Kwaliteitsscore voor Alcon is 5/10.
De ISIN van Alcon is CH0432492467. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Alcon is A2PDXE. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Alcon is ALC.SW. Onder dit beurstickersymbool wordt het Alcon-aandeel op de beurs verhandeld.
Alcon aandeel
Alcon Peer Group
Alcon Ticker
Alcon FIGI
Alle fundamentals en diepgaande analyse van Alcon
Onze aandelenanalyse van het Alcon-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Alcon. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: